Characteristics | Patients |
---|---|
Age (years) | |
Median (range) | 76 (63–89) |
Gender | |
Male | 14 (87 %) |
Female | 2 (13 %) |
Performance status | |
0 | 9 (56 %) |
1 | 5 (31 %) |
2 | 2 (13 %) |
Follow-up time (months) | |
Median (range) | 14 (5–39) |
T categorya (n = 15) | |
T1 | 7 (47 %) |
T2 | 6 (40 %) |
T3 | 2 (13 %) |
Stagea (n = 15) | |
I | 12 (80 %) |
II | 3 (20 %) |
Histopathology | |
Squamous cell carcinoma | 7 (44 %) |
Adenocarcinoma | 2 (13 %) |
Small cell carcinoma | 1 (6 %) |
Clinical malignancy | 5 (31 %) |
Metastasis (lung cancer) | 1 (6 %) |
Diameter of lung tumor (mm) | |
Median (range) | 24 (15–60) |
Total dose (Gy (RBE)) | |
Median (range) | 80 (66.0–86.4) |